Sage Therapeutics Inc (SAGE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

215 FIRST STREET CAMBRIDGE, MA 02142

Sage Therapeutics, Inc. develops treatments for central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions.

Data based on most recent fiscal year report
Market Cap5.886 Billion Shares Outstanding41.05 Million Avg Volume937.737 Thousand
1-Yr BETA vs S&P TR Current Ratio10.11 Quick Ratio10.11
View SEC Filings from SAGE instead.
Q2 2019 All Institutions Hedge Funds 1
To trade SAGE now:
Filers who had this stock in their top 10: 7 3 (0.31%)
13F Filers holding this stock: 260 33 (3.41%)
Aggregate 13F shares on 06/30/2019: 57.45 Million 3.159 Million
Aggregate 13F shares on 03/31/2019: 55.785 Million 4.406 Million
Percent change: 2.99% -28.30%
Funds creating new positions: 44 9
Funds Adding to an existing position: 95 5
Funds closing out their position: 34 9
Funds reducing their position: 81 13
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SAGE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

10.6 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NELSEN ROBERT

  • Director
  • 10% Owner
444,444 2019-10-10 0

PIEN HOWARD H

  • Director
16,400 2019-10-01 0

FRATES JAMES M SVP, ALKS INC; CFO ALKS

  • Officer
213,925 2019-09-13 4

JONAS JEFFREY M PRESIDENT & CEO

47,030 2019-09-11 9

KANES STEPHEN CHIEF MEDICAL OFFICER

8,292 2019-09-04 6

ROBICHAUD ALBERT CHIEF SCIENTIFIC OFFICER

95,657 2019-07-25 5

IGUCHI KIMI CFO & TREASURER

12,409 2019-07-25 8

COOK ANNE MARIE SVP, GC & SECRETARY

1,756 2019-07-25 5

CLOONAN MICHAEL CHIEF BUSINESS OFFICER

2,102 2019-07-25 3

PAUL STEVEN M PRESIDENT & CEO

  • Officer
  • Director
106,485 2019-07-02 7

COLA MICHAEL F

  • Director
15,000 2019-06-13 1

STARR KEVIN P

0 2019-06-05 2

GERMANO GENO J

0 2019-06-05 2

NAYAK ASHA

0 2019-06-05 1

GOLUMBESKI GEORGE

0 2019-06-05 3

BARRETT ELIZABETH

0 2019-06-05 3

STEBEN KENNETH E PRESIDENT, CEO

  • Officer
  • Director
247 2019-04-01 0

THIRD ROCK VENTURES II, L.P.

THIRD ROCK VENTURES GP II, L.P.

TRV GP II, LLC

LEVIN MARK J

TEPPER ROBERT I

  • 10% Owner
No longer subject to file 2018-03-07 0

ANDERSON THOMAS SEE REMARKS

0 2017-02-06 0

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

  • 10% Owner
4,637,137 2016-07-06 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

JONAS JEFFREY M PRESIDENT & CEO

2019-09-11 M 4,600 $0.45 a 47,030 47,030.00 direct

JONAS JEFFREY M PRESIDENT & CEO

2019-09-11 M 4,600 d 60,387 47,030.00 direct

KANES STEPHEN CHIEF MEDICAL OFFICER

2019-09-04 M 6,000 $0.45 a 8,292 8,292.00 direct

KANES STEPHEN CHIEF MEDICAL OFFICER

2019-09-04 M 6,000 d 86,100 8,292.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments